Difference between revisions of "Edoxaban (Savaysa)"
Jump to navigation
Jump to search
m |
|||
| Line 16: | Line 16: | ||
==Also known as== | ==Also known as== | ||
| − | DU-176b | + | *'''Code name:''' DU-176b |
| + | *'''Brand name:''' Savaysa | ||
==References== | ==References== | ||
| Line 22: | Line 23: | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| + | [[Category:Oral medications]] | ||
[[Category:Factor Xa inhibitors]] | [[Category:Factor Xa inhibitors]] | ||
Revision as of 02:21, 28 November 2017
General information
Class/mechanism: Factor Xa inhibitor, acts at the active site of factor Xa to inhibit its actions in the coagulation cascade.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
History of changes in FDA indication
- 1/8/2015: FDA approved
- "for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant."
- "To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF)."
Also known as
- Code name: DU-176b
- Brand name: Savaysa